Jails Are Killing People With a Drug Withdrawal They Refuse to Treat as Medicine

Chris was doing what he was supposed to do. Locked up at the Allegheny County Jail outside Pittsburgh, he got onto the jail’s medication program, took what the nurses gave him, followed the protocol clinicians had built specifically for the new thing showing up in the drug supply. He still had two heart attacks. He’s dead now. The drug that did it to him isn’t even an opioid — it’s a horse tranquilizer, and it’s in almost every bag of fentanyl in the Northeast right now, and most of the jails booking people this week have no idea what they’re dealing with, according to STAT’s reporting from inside Allegheny County’s jail health unit.

The drug is medetomidine — vets call it “dex,” and until three years ago its only real job was sedating dogs and zoo animals before surgery. Since 2021 it’s been showing up cut into street fentanyl, and the numbers on how fast that’s happening should stop you cold: reports to the national forensic lab database jumped from 247 in 2023 to 2,616 in 2024 to 8,233 in 2025 — a 33-fold increase in two years. In CDC’s sentinel testing sites across the Northeast, it’s now turning up in nearly three-quarters of opioid samples. If you’re using in Philadelphia, Baltimore, or Pittsburgh right now, you are very likely also using medetomidine, whether anyone told you or not.

Here’s the part that should be driving jail policy this week, and mostly isn’t:

A jail that won’t treat medetomidine withdrawal as a medical emergency is choosing, by default, to let people have heart attacks in a cell.

That’s not rhetorical. In a case series published in CDC’s Morbidity and Mortality Weekly Report, 165 people hospitalized across three Philadelphia health systems for medetomidine-complicated fentanyl withdrawal had a median heart rate of 145 beats per minute and blood pressure readings of 195 over 122 — numbers that would trigger a stroke workup in anyone walking into an ER off the street. Ninety-one percent of those patients needed intensive care. Twenty-four percent needed a breathing tube. Three developed a brain injury called posterior reversible encephalopathy syndrome — think of it as the brain’s blood vessels seizing up under the blood-pressure spike, sometimes causing seizures or vision loss. This isn’t dopesickness with extra steps. It’s a cardiovascular event wearing a withdrawal costume, and jails are receiving it with a shrug and an ibuprofen tablet.

Jails Built Their Withdrawal Protocols for a Drug Supply That No Longer Exists

Every county jail intake protocol in America was written for a version of opioid withdrawal that hasn’t reflected street reality for years — first because of xylazine, the veterinary sedative that caused flesh wounds and rewired detox timelines starting around 2021, and now because of medetomidine, which is even more dangerous and, according to CDC’s April 2026 situation summary, doesn’t respond to the medications that used to work for fentanyl or xylazine withdrawal. Standard withdrawal orders — clonidine at low, cautious doses, maybe a benzodiazepine taper, comfort meds for nausea — were built around opioid receptors. Medetomidine doesn’t work on opioid receptors. It’s an alpha-2 agonist, meaning it hijacks a completely different set of nerve signals that control blood pressure and alertness, and pulling it away triggers an autonomic storm — the body’s “fight or flight” wiring firing without a stop switch — that standard opioid protocols were never built to catch, let alone treat.

The one thing that reliably worked in the Philadelphia case series was more of the same class of drug in a controlled dose: dexmedetomidine infusion, titrated carefully in a hospital, which brought symptoms under control in 83 percent of patients who received it. That’s an IV medication requiring monitoring equipment most jail infirmaries don’t have and, in many cases, aren’t legally staffed to administer. A national survey following the Department of Justice’s 2022 guidance found fewer than half of U.S. jails offer any FDA-approved medication for opioid use disorder at all — the DOJ guidance itself states plainly that a jail refusing to continue a detainee’s prescribed medication for opioid use disorder can be committing disability discrimination under the Americans with Disabilities Act. That’s the floor. Medetomidine asks jails to clear a bar several feet above the floor they’re already failing to reach.

A national survey following the Department of Justice’s 2022 guidance found fewer than half of U.S.

Michael Lynch, a physician at the University of Pittsburgh Medical Center who started noticing patients showing up with an unusually severe withdrawal presentation in the fall of 2024, has been trying to get ahead of it since — building protocols, briefing other facilities, pushing the idea that aggressive early treatment with buprenorphine can help clinicians spot a medetomidine case before it turns into a cardiac event. But protocols travel slower than drug supply, and the lag isn’t abstract to the people who watched it happen inside the walls: Bethany Hallam has said she is aware of “numerous people who’ve waited days after being arrested to continue their MOUD,” a delay that can push someone into a withdrawal nobody planned for and nobody is watching closely enough to catch — a pattern her own advocacy on the jail’s oversight board has been trying to close. Chicago saw a cluster of confirmed and suspected medetomidine overdoses as far back as May 2024. Pittsburgh saw its own surge that fall. Maryland’s public health department was still putting out warnings about rising medetomidine detections in Baltimore as recently as June 24, 2026. The drug supply moves at the speed of a supply chain. Correctional healthcare policy moves at the speed of a budget cycle.

The One Jail That Built a Real Response Is the Exception, Not the Model

Allegheny County Jail is, by the accounts of the clinicians and advocates working inside it, the closest thing the country has to a jail that takes this seriously — and it got there through years of outside pressure, not institutional foresight. Bethany Hallam, a member of the Allegheny County Council who is herself in long-term recovery after developing an opioid use disorder from a prescription and cycling through the same jail she now oversees, has spent years pushing for the jail to stop making people wait, sometimes for days, to restart medications they were already prescribed on the outside — a gap that PublicSource’s reporting on the jail’s medication program found was pushing some people into unsupervised, unnecessary detox behind bars. Nurse practitioner Stuart Fisk and addiction medicine director Elizabeth Ferro used opioid settlement money — the fund every state built from suing the companies that flooded America with prescription pills — to build out clinical staffing precisely because they knew emerging drugs like medetomidine were coming and the jail had no plan.

That history matters because it tells you what it actually takes to fix this: money that isn’t discretionary, a formerly incarcerated person with the standing to sit on the oversight board and force the issue year after year, and clinicians willing to treat a cell block like a hospital ward. Most of the roughly 3,000 jails in this country have none of those three things. If you’re inside right now, or you have someone inside right now, the honest version of this story is that your jail is probably not Allegheny County — and the medication you were taking on the outside, whether it was methadone, buprenorphine, or something for blood pressure that keeps a withdrawal event from turning fatal, is not guaranteed to keep coming with you through the door.

A Bill Sitting in the Senate Right Now Is the Other Half of This Story

Two days before STAT’s reporting on the jail crisis ran, Senators Ed Markey and Rand Paul reintroduced the Modernizing Opioid Treatment Access Act 2.0, a bill that would let board-certified addiction medicine doctors prescribe methadone for regular pharmacy pickup instead of forcing patients through the current system: roughly 2,000 specialized clinics nationwide, many demanding a daily in-person visit before dispensing a single dose. This is not a new idea — the same bill passed the Senate HELP Committee on a bipartisan vote back in December 2023 and then died without a floor vote, after private equity firms that own stakes in about a third of the nation’s methadone clinics ran a lobbying campaign against it under the banner “Program, Not a Pill.” Markey’s own framing of the bill hasn’t changed because the underlying problem hasn’t: “Methadone for opioid use disorder is locked behind arcane laws that criminalize and stigmatize people in recovery,” he said of the legislation, “this outdated system is costing lives.” Paul, from the other side of the aisle, put it in the language of medical autonomy: “This bipartisan legislation will return treatment decisions to health care providers, who know their patients best.” It’s a real bill, reintroduced, not yet law — Senate passage, a House companion, and a presidential signature all still stand between this text and anyone’s pharmacy counter.

Connect the two stories and the shape of the failure gets clearer. Almost 5 million Americans have an opioid use disorder and fewer than 1 in 5 get treatment, partly because methadone access is bottlenecked behind a clinic system built in the 1970s out of fear, not medicine. People with unmanaged opioid use disorder cycle through jail at high rates. Jails are now facing a withdrawal syndrome that is measurably more lethal than the one their protocols were built for. Every one of those facts makes the other worse. A methadone system that actually reached people before arrest would shrink the population walking into jail intake mid-withdrawal in the first place. Read more on the policy fight over addiction treatment funding and how it connects to what’s cut into the opioid supply right now.

Jails are now facing a withdrawal syndrome that is measurably more lethal than the one their protocols were built for.

The Country Has Been Here Before, With a Different Drug and the Same Excuse

This is not the first time a chemical shift in the street supply has outrun the institutions supposed to respond to it, and it is not the first time the response has been to treat the people using as the problem rather than the drug. When xylazine — another veterinary sedative — spread through the fentanyl supply starting around 2021, it took nearly two years and a wave of amputations and open wounds documented by journalists and researchers before FDA issued a formal alert and jails began even acknowledging it existed. Before that, the template was methadone itself: introduced in the 1960s as the most effective treatment medicine addiction science has ever produced, then deliberately quarantined into standalone clinics — separate from ordinary medical care, subject to daily-visit rules no other chronic disease treatment carries — because lawmakers in the 1970s decided people who used drugs needed to be watched, not simply treated. That decision is the reason methadone still isn’t at your regular pharmacy more than fifty years later, and it is the direct ancestor of the “Program, Not a Pill” fight happening in the Senate this week. Every time the drug supply mutates, institutions built on suspicion instead of medicine take years to catch up, and the people paying for that lag are never the ones who designed the system.

If you are in withdrawal tonight, or coming off something that might have medetomidine in it, the single most reliable thing that hasn’t changed is this: naloxone still works on the fentanyl and reverses the opioid overdose, even when medetomidine is also in the mix — it just won’t touch the medetomidine withdrawal itself, so a racing heart, blood pressure that feels like your skull is going to split, or fading in and out of alertness after the opioid symptoms should already have passed is your body telling you this is the other drug, and it needs an ER, not a waiting room. That’s true whether you’re free or in a cell, and it’s true whether or not the intake nurse knows what medetomidine is. You are allowed to describe your own withdrawal accurately to whoever is supposed to be treating you, and you are allowed to ask, by name, for the medication you were already prescribed.

Chris did what the system asked. He got into the program, took the treatment that was supposed to work, and the drug still took him — because “the program” wasn’t built for what’s actually in the supply now, and most jails haven’t even gotten that far. The people who will decide whether the next Chris survives are not in a lab or a hearing room. They’re jail medical directors deciding this month whether to write a new protocol before their first medetomidine case shows up, and two senators trying, for the third time since 2023, to get a floor vote before the next private equity ad campaign buries it again. Neither decision requires new science. The clinical playbook already exists in Pittsburgh and Philadelphia. It just hasn’t been ordered into the next county over yet.